c-Myc tag Peptide: Precision Tool for Transcription Factor Regulation and Immunoassays

Executive Summary: The c-Myc tag Peptide (A6003) is a synthetic peptide corresponding to the C-terminal amino acids 410–419 of human c-Myc protein. It is widely used to displace c-Myc-tagged fusion proteins in immunoassays, allowing precise inhibition of anti-c-Myc antibody binding (Wu et al., 2021). c-Myc is a proto-oncogene encoding a transcription factor that regulates cell proliferation, apoptosis, and gene amplification in cancer biology. The peptide demonstrates high solubility (≥60.17 mg/mL in DMSO, ≥15.7 mg/mL in water with ultrasonic treatment) and is stable when stored desiccated at -20°C. This dossier presents evidence, applications, and boundaries for the c-Myc tag Peptide in research workflows, with a focus on its molecular specificity and translational value for cancer and immunology studies.

Biological Rationale

c-Myc is a well-characterized transcription factor critical to cell cycle progression, growth, apoptosis, and stem cell maintenance. It functions by binding DNA and regulating gene expression, notably upregulating cyclins and ribosomal proteins while suppressing cell cycle inhibitors like p21 and anti-apoptotic factors such as Bcl-2 [Product Page]. Aberrant c-Myc activation is implicated in gene amplification and tumorigenesis, making it a central focus in cancer research. Synthetic peptides mimicking c-Myc epitopes, such as the c-Myc tag Peptide, enable precise molecular assays to study these regulatory pathways and protein interactions [Related Article].

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide contains the sequence EQKLISEEDL, matching the C-terminal epitope (amino acids 410–419) of the human c-Myc protein. This region is recognized by monoclonal anti-c-Myc antibodies in immunoassays, including Western blot, immunoprecipitation, and ELISA. By competitively binding these antibodies, the peptide efficiently displaces c-Myc-tagged fusion proteins, thereby inhibiting antibody-antigen interactions in a concentration-dependent manner [Contrast: This article expands on troubleshooting and mechanistic details compared to Type-II Collagen Fragment’s protocol focus]. This displacement is highly specific, leveraging the epitope’s unique amino acid sequence.

Evidence & Benchmarks

• c-Myc tag Peptide (EQKLISEEDL) binds monoclonal anti-c-Myc antibodies with high specificity, enabling displacement of c-Myc-fusion proteins in immunoassays (Wu et al. 2021, https://doi.org/10.1080/15548627.2020.1761653).
• The peptide is soluble at ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (ultrasonic treatment, 25°C), but insoluble in ethanol (Product Page).
• c-Myc regulates transcription of genes involved in cell proliferation, apoptosis, and ribosome biogenesis, directly impacting cancer cell fate (Wu et al., 2021, DOI).
• c-Myc-driven gene amplification is a hallmark of many human cancers and is a validated target for translational research (This article provides further mechanistic modulation insights compared to EpitopePeptide’s gene amplification focus).
• Storage at -20°C and use of desiccated peptide ensures long-term stability; solution storage beyond 1 week at 4°C is not recommended (Product Page).

Applications, Limits & Misconceptions

Primary Applications:

• Immunoassays: Competitive displacement of c-Myc-tagged fusion proteins from anti-c-Myc antibodies in Western blot, ELISA, and IP workflows.
• Antibody specificity validation: Controls for distinguishing true versus nonspecific antibody binding.
• Transcription factor research: Probing c-Myc’s role in gene regulation and oncogenesis.
• Cancer biology: Functional studies of proto-oncogene c-Myc and gene amplification in tumor models.

Common Pitfalls or Misconceptions

• The c-Myc tag Peptide does not inhibit endogenous c-Myc protein function in living cells; it acts only in vitro as a competitive reagent.
• It cannot be used for diagnostic or therapeutic purposes; for research use only.
• Peptide is insoluble in ethanol; use DMSO or water (with sonication) for reconstitution.
• Long-term storage of peptide solutions at room temperature or 4°C reduces stability and activity.
• The peptide does not interfere with unrelated antibody-antigen interactions.

Workflow Integration & Parameters

The c-Myc tag Peptide (A6003) integrates seamlessly into immunoassays requiring precise displacement of c-Myc-tagged proteins. Typical workflows include:

• Reconstitution: Dissolve peptide at ≥60.17 mg/mL in DMSO or ≥15.7 mg/mL in water using ultrasonic treatment (room temperature, pH 7.2–7.4).
• Storage: Store dry, desiccated peptide at -20°C; avoid repeated freeze-thaw cycles.
• Application: Add peptide to immunoassay at concentrations optimized for antibody displacement (typically 1–10 μg/mL); incubate for 30–60 minutes at 4°C or room temperature.
• Controls: Include negative controls (no peptide) and positive controls (known c-Myc substrate) to assess specificity.

For protocol troubleshooting, see guidance in this resource, which this article extends by benchmarking specificity and practical concentration ranges.

Conclusion & Outlook

The c-Myc tag Peptide is a rigorously validated reagent for precise manipulation of c-Myc antibody interactions in immunoassays. Its specificity and robust solubility profiles make it essential for transcription factor studies and cancer research. While it cannot modulate endogenous c-Myc in live cells, it remains indispensable for in vitro assay development and antibody validation. For future applications, combining this reagent with advanced autophagy and immune signaling studies will further elucidate transcription factor regulation in oncology. For additional mechanistic and translational insights, compare with this article, which this review expands by integrating autophagy-mediated stability mechanisms into c-Myc research contexts.